Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy.

Akiko AbeMasao YuasaYoshie ImaiTomohiro KagawaAyuka MinedaMasato NishimuraChisato TonoisoAkiko KuboTakashi KawanakaHitoshi IkushimaTakeshi Iwasa

Published in: International journal of clinical oncology (2022)

Our findings emphasize the importance of assessing original nutritional status and maintaining muscle mass and quality during the treatment of patients with cervical cancer.

Keyphrases

poor prognosis
skeletal muscle
long non coding rna
locally advanced
rectal cancer
quality improvement
insulin resistance
climate change
type diabetes
metabolic syndrome
radiation therapy
replacement therapy
combination therapy
newly diagnosed
mesenchymal stem cells